Development of NP-Based Universal Vaccine for Influenza A Viruses
Vaccines (Basel). 2024 Feb 2;12(2):157. doi: 10.3390/vaccines12020157.ABSTRACTThe nucleoprotein (NP) is a vital target for the heterosubtypic immunity of CD8+ cytotoxic T lymphocytes (CTLs) due to its conservation among influenza virus subtypes. To further enhance the T cell immunity of NP, autophagy-inducing peptide C5 (AIP-C5) from the CFP10 protein of Mycobacterium tuberculosis was used. Mice were immunized intranasally (i.n.) with human adenoviral vectors, HAd-C5-NP(H7N9) or HAd-NP(H7N9), expressing NP of an H7N9 influenza virus with or without the AIP-C5, respectively. Both vaccines developed similar levels of NP-spec...
Source: Cancer Control - February 24, 2024 Category: Cancer & Oncology Authors: Ekramy E Sayedahmed Nelly O Elshafie Andrea P Dos Santos Chinnaswamy Jagannath Suryaprakash Sambhara Suresh K Mittal Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response
Int Immunopharmacol. 2024 Feb 22;130:111710. doi: 10.1016/j.intimp.2024.111710. Online ahead of print.ABSTRACTInfluenza virus is a kind of virus that poses several hazards of animal and human health. Therefore, it is important to develop an effective vaccine to prevent influenza. To this end we successfully packaged recombinant adenovirus rAd-NP-M2e-GFP expressing multiple copies of influenza virus conserved antigens NP and M2e and packaged empty vector adenovirus rAd-GFP. The effect of rAd-NP-M2e-GFP on the activation of dendritic cell (DC) in vitro and in vivo was detected by intranasal immunization. The results showed t...
Source: International Immunopharmacology - February 23, 2024 Category: Allergy & Immunology Authors: Yi-Bing Lian Man-Jie Hu Tian-Kui Guo Yong-Lei Yang Rong-Rong Zhang Jing-Shu Huang Ling-Jiao Yu Chun-Wei Shi Gui-Lian Yang Hai-Bin Huang Yan-Long Jiang Jian-Zhong Wang Xin Cao Nan Wang Yan Zeng Wen-Tao Yang Chun-Feng Wang Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | PMC:PMC10899815 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | PMC:PMC10899815 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Venous Thrombosis in Airborne Viral Infections: Is Coronavirus Disease 2019 now Any Different from Influenza?
Semin Thromb Hemost DOI: 10.1055/s-0044-1780507One of the hallmarks of coronavirus disease 2019 (COVID-19), particularly in complicated cases (i.e., requiring hospitalization or intensive care support), is persistent hemostasis activation, which may be associated with a vast array of thrombotic episodes involving both the arterial and venous systems. The renewed emphasis on the relationship between viral infections and venous thrombosis paves the way for determining whether a more common and often underestimated infection disease, such as influenza, may also be associated with a significant burden of venous thrombotic epis...
Source: Seminars in Thrombosis and Hemostasis - February 23, 2024 Category: Hematology Authors: Lippi, Giuseppe Favaloro, Emmanuel J. Nocini, Riccardo Tags: Review Article Source Type: research
